Arevirumab-3 biosimilar – Anti-Lassa virus glycoprotein mAbs – Research Grade from ProteoGenix; catalogue PX-TA2106; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Title: Arevirumab-3 Biosimilar: A Promising Anti-Lassa Virus Glycoprotein mAb for Therapeutic Targeting
Arevirumab-3 biosimilar is a monoclonal antibody (mAb) that specifically targets the glycoprotein of Lassa virus, a deadly pathogen responsible for causing Lassa fever. This biosimilar is a promising therapeutic option for treating Lassa virus infection, as it has shown potent antiviral activity and has the potential to be a cost-effective alternative to the original Arevirumab-3.
Arevirumab-3 biosimilar is a recombinant mAb that is produced using advanced biotechnology techniques. It is a chimeric antibody, meaning it contains both human and mouse components. The variable regions of the antibody are derived from a mouse mAb that specifically binds to the glycoprotein of Lassa virus, while the constant regions are derived from human antibodies. This unique structure allows for high specificity and efficacy in targeting the Lassa virus glycoprotein.
The main activity of Arevirumab-3 biosimilar is its ability to bind to the glycoprotein of Lassa virus, preventing the virus from entering and infecting host cells. This binding also triggers the immune system to recognize and destroy the virus. In addition, Arevirumab-3 biosimilar has been shown to have neutralizing activity against Lassa virus, meaning it can block the virus from replicating and spreading in the body. This activity makes it a potent antiviral agent against Lassa virus infection.
Arevirumab-3 biosimilar is currently being developed as a research grade mAb, with the aim of eventually becoming a therapeutic option for treating Lassa fever. Its potential applications include:
1. Treatment of Acute Lassa Fever:
The primary application of Arevirumab-3 biosimilar is in the treatment of acute Lassa fever. This biosimilar can be administered to patients who have been diagnosed with Lassa virus infection, to help reduce the severity of symptoms and improve the chances of survival. Its high specificity and neutralizing activity make it a promising candidate for this application.
2. Prophylactic Treatment:
Arevirumab-3 biosimilar can also be used as a prophylactic treatment for individuals who are at high risk of contracting Lassa virus infection, such as healthcare workers and individuals living in Lassa fever-endemic regions. By administering this biosimilar, the risk of infection can be significantly reduced.
3. Research Tool:
As a research grade mAb, Arevirumab-3 biosimilar can also be used as a tool for studying the mechanisms of Lassa virus infection and for developing new therapies. Its specific binding to the virus glycoprotein can help researchers better understand the virus and its interactions with host cells.
In conclusion, Arevirumab-3 biosimilar is a promising mAb with high specificity and potent antiviral activity against Lassa virus. Its unique structure, activity, and potential applications make it a valuable therapeutic option for treating Lassa fever. Further research and development of this biosimilar could lead to its approval as a safe and effective treatment for this deadly disease.
ProteoGenix catalogue number PX-TA2106. For research use only.
Target: Arevirumab-3 biosimilar – Anti-Lassa virus glycoprotein mAbs – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Arevirumab-3 biosimilar – Anti-Lassa virus glycoprotein mAbs – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
